Imaging in cell-based therapy for neurodegenerative diseases

  • Deniz Kirik
  • Nathalie Breysse
  • Tomas Björklund
  • Laurent Besret
  • Philippe Hantraye
Supplement

DOI: 10.1007/s00259-005-1909-6

Cite this article as:
Kirik, D., Breysse, N., Björklund, T. et al. Eur J Nucl Med Mol Imaging (2005) 32(Suppl 2): S417. doi:10.1007/s00259-005-1909-6

Abstract

Fetal cell transplantation for the treatment of Parkinson’s and Huntington’s diseases has been developed over the past two decades and is now in early clinical testing phase. Direct assessment of the graft’s survival, integration into the host brain and impact on neuronal functions requires advanced in vivo neuroimaging techniques. Owing to its high sensitivity, positron emission tomography is today the most widely used tool to evaluate the viability and function of the transplanted tissue in the brain. Nuclear magnetic resonance techniques are opening new possibilities for imaging neurochemical events in the brain. The ultimate goal will be to use the combination of multiple imaging modalities for complete functional monitoring of the repair processes in the central nervous system.

Keywords

Parkinson’s disease Huntington’s disease Cell transplantation Positron emission tomography Magnetic resonance imaging 

Abbreviations

AADC

aromatic l-amino acid decarboxylase

AD

Alzheimer’s disease

ADC

apparent diffusion coefficient

BOLD

blood oxygen level dependent

CIT

2-β-carbomethoxy-3-β-(4-iodophenyl)tropane

CNTF

ciliary neurotrophic factor

Cr

creatine

DA

dopamine

DAT

dopamine transporter

DTBZ

dihydrotetrabenazine

DTI

diffusion tensor imaging

DWI

diffusion-weighted imaging

FDG

fluorodeoxyglucose

GABA

γ-aminobutyric acid

GAPDH

glyceraldehyde phosphate dehydrogenase

Gd

gadolinium

HAP

Huntington-associated protein

HD

Huntington’s disease

l-DOPA

3,4-dihydroxyphenylalanine

MAO

monoamine oxidase

MRI

magnetic resonance imaging

MRS

magnetic resonance spectroscopy

MSA-P

striatonigral variant of multiple system atrophy

NAA

N-acetylaspartate

NADPH

nicotinamide adenine dinucleotide phosphate

NMDA

N-methyl-d-aspartate

NMR

nuclear magnetic resonance

NOS

nitric oxide synthase

PCr

phosphocreatine

PD

Parkinson’s disease

PE2I

N-(3-iodoprop-(2E)-enyl)-2β-carboxymethoxy-3β-(4′-methylphenyl)nortropane

PET

positron emission tomography

PIB

Pittsburg Compound-B

SNc

substantia nigra pars compacta

VTA

ventral tegmental area

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Deniz Kirik
    • 1
  • Nathalie Breysse
    • 1
  • Tomas Björklund
    • 1
  • Laurent Besret
    • 2
  • Philippe Hantraye
    • 2
  1. 1.Section for Neuroscience, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Disease Modeling GroupLund UniversityLundSweden
  2. 2.URA CEA CNRS 2210 Isotopic Imaging UIIBP Unit and Program ImageneService Hospitalier Frédéric JoliotOrsayFrance

Personalised recommendations